Scale-up from Lab to Commercial Production: The Process Vessel Challenge Nobody Talks About
In pharmaceutical and biopharmaceutical manufacturing, breakthroughs often begin in controlled laboratory environments where formulations are developed in 5L, 10L, or 50L vessels. At this stage, process parameters are tightly monitored, batch volumes are manageable, and production seems highly predictable. Then comes commercialization.
The transition from a 10L R&D vessel to a 10,000L or 50KL commercial production system often appears straight forward on paper—simply use a larger vessel and replicate the same process parameters.
But scale-up is where many pharmaceutical companies face their biggest operational setbacks.
Batch inconsistencies begin to appear. Mixing times increase. Heating cycles become longer. Sterility risks multiply. Validation becomes more complex.
And at the center of these issues lies a critical piece of equipment many companies underestimate:
The process vessel.
Why Scale-up Is Not Just About Increasing Vessel Size
One of the most common assumptions in pharmaceutical manufacturing is that scale-up production simply means increasing batch volume while maintaining the same operating conditions.
However, process physics changes dramatically with vessel size.
A formulation that mixes perfectly in a 10L vessel may behave entirely differently in a 10,000L system because:
• Fluid flow dynamics change
• Heat transfer efficiency reduces
• Shear rates vary
• Product settling may occur
• Sterility complexity increases
This is where process vessel engineering becomes critical.
The Mixing Challenge: Why Bigger Tanks Don’t Behave the Same
Mixing is often the first major problem during scale-up.
In small lab vessels:
• Ingredients disperse quickly
• Fluid circulation is predictable
• Mixing times are shorter
In larger vessels:
• Dead zones may develop
• Powder dissolution slows down
• Product settling becomes common
• Shear-sensitive molecules may degrade
This becomes especially critical for:
• Vaccines
• Biosimilars
• Monoclonal antibodies
• Ophthalmics
• Sterile injectables
To understand this, consider impeller tip speed, which directly affects shear forces.
Tip Speed=πDN
Where:
• D = Impeller diameter
• N = Rotational speed
Lab Scale-up Example:
A 10L vessel may use:
• Impeller diameter = 0.1 m
• Speed = 300 RPM
Tip Speed=π(0.1)(5)=1.57 m/s
Commercial Scale-up Example:
If the production vessel has a 1-meter impeller:
N=1.57 / π(1)=30 RPM
Running the larger vessel at the same 300 RPM would create excessive shear and potentially damage sensitive biologics
Power Demand Increases Faster Than Most Teams Expect
Many manufacturers underestimate the energy required for large mixing.
Power consumption follows this equation:
P=Np ρN3 D5
Because power depends on D⁵, increasing impeller diameter dramatically increases power demand.
For example:
(0.1)5 / (1)5 = 100,000
A poorly optimized scale-up strategy can significantly increase energy consumption and operational costs.
Heat Transfer Becomes a Major Bottleneck
Temperature control is critical in sterile manufacturing.
At lab scale-up, heating and cooling happen quickly due to smaller volumes.
At commercial scale-up, thermal efficiency drops significantly.
Heat required follows:
Q=mCp ΔT
For a 10L batch:
Q=10(4.18)(60)=2508 kJ
For a 10,000L batch:
Q=10,000(4.18)(60)=2,508,000 kJ
This explains why larger systems require:
• Efficient jackets
• Limpet coils
• Proper insulation
• Advanced thermal automation
Surface Area Shrinks Relative to Volume
Another hidden challenge is declining surface area-to-volume ratio.
SA : V = 3/r
As vessel radius increases:
• Surface area per unit volume decreases
• Heat transfer slows
• Cooling cycles become longer
This often delays production schedules.
Sterility Risks Multiply at Commercial Scale-up
As vessel systems grow larger, so do contamination risks.
Additional components include:
• Pumps
• Transfer lines
• Valves
• Sensors
• Filtration skids
• Sampling ports
Every additional connection increases contamination risk.
Poor design may introduce:
• Dead legs
• Incomplete drainage
• Inefficient SIP cycles
• Manual intervention points
For sterile manufacturing, even one contamination event can lead to complete batch rejection.
Cleaning Costs Increase Rapidly
CIP requirements expand significantly during scale-up.
A lab vessel may consume:
• 50L per cleaning cycle
A commercial vessel may consume:
• 5,000L per cycle
At two cycles per day:
5000×2=10,000 L/day
Annual consumption becomes:
10,000×365=3.65 million liters/year
This directly impacts sustainability targets and utility costs.
The Financial Impact of Poor Scale-Up
Scale-up failures can become extremely expensive.
If one biologics batch is worth ₹2 crore and two batches fail annually:
2×₹2 crore=₹4 crore/year
This excludes:
• Validation delays
• Regulatory setbacks
• Lost market opportunities
Why Custom Process Vessel Design Matters
No two pharmaceutical products behave the same way.
A vessel designed for oral syrups may fail in:
• Vaccines
• Biosimilars
• Cell culture media
• Buffer preparation
• High-shear formulations
Modern process vessels must be customized for:
• Product sensitivity
• Batch size
• Mixing requirements
• Sterility requirements
• Automation needs
• Future scalability
Final Thoughts
Scale-up in pharmaceutical production is not simply about making larger batches.
It’s about understanding how physics, engineering, sterility, and automation evolve at larger volumes.
The right process vessel accelerates commercialization.
The wrong one can delay product launches, increase costs, and compromise product quality.
And that’s the process vessel challenge nobody talks about—but every growing pharmaceutical company eventually faces.
